We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

OctoPlus' Licensee Biolex Commences Phase IIb Study with Locteron

News   Apr 22, 2009

 
OctoPlus' Licensee Biolex Commences Phase IIb Study with Locteron
 
 
 

RELATED ARTICLES

Infrared to Visible Light: A Novel Route to Photodynamic Therapy & Drug Development

News

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

READ MORE

Targeted Photodynamic Therapy Stops Tumor Growth in 70% of Mice

News

A team of scientists has experimentally proved the effectiveness of the formerly suggested "light" method in oncotherapy. In a series of laboratory preclinical tests, the tumor growth stopped in 70% of mice.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE